Semaglutide, GLP-1, is a naturally occurring peptide known to lower blood sugar levels and enhance insulin secretion. Research shows that GLP-1 may also improve heart, liver, and lung function while helping to slow or prevent the effects of Alzheimer’s disease. GLP-1 has been shown to significantly decrease appetite by delaying gastric emptying and reducing intestinal motility. Glucagon-Like Peptide-1 (GLP-1) Analog Shown to Stimulate Insulin and Suppress Glucagon Secretion in a Glucose-Dependent Manner
What is Semaglutide?
Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion, which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying. It was first developed in 2012 by Novo Nordisk as a longer-acting option to Liraglutide. In 2017 this drug was approved as an anti-diabetic medication used to treat type 2 diabetes and obesity. In June 2021, it got approved for chronic weight management in obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.
Benefits of Semaglutide Over Time
- Reduces food intake by lowering appetite
- Slows food digestion in the stomach
- Decrease body fat percentage & weight loss
- Decreased cardiovascular outcomes in subjects with type 2 diabetes
- Lower HbA1c levels
- Enhance the growth of β cells in the pancreas